Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours (STREET)

Ipsen

Status: Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumours

Study type: Observational

Funder types: Industry

Identifiers

NCT02788565

A-SE-52030-353

Details and patient eligibility

About

Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.

Enrollment: 156 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) and treated with SSA for at least three months but not more than 3 years
• GEP-NET proliferation index Ki 67 <10%
• Over 18 years of age

Exclusion criteria

• No specific exclusion criteria defined